• Publications
  • Influence
Abiraterone in metastatic prostate cancer without previous chemotherapy.
BACKGROUND Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated thisExpand
  • 1,958
  • 69
  • PDF
Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
PURPOSE To update the American Society of Clinical Oncology (ASCO) guideline for antiemetics in oncology. METHODS A systematic review of the medical literature was completed to inform this update.Expand
  • 521
  • 15
  • PDF
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.
New therapeutic approaches for castration-resistant prostate cancer (CRPC) introduce new treatment dilemmas: how best to sequence these options to maximally benefit patients, what tests to performExpand
  • 176
  • 8
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer:
BACKGROUND Bone metastases are a major cause of morbidity in metastatic castration-resistant prostate cancer. Abiraterone acetate potently disrupts intracrine androgen receptor signalling pathwaysExpand
  • 252
  • 6
A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment
PurposePatients with cancer experience acute and chronic symptoms caused by their underlying disease or by the treatment. While numerous studies have examined the impact of various treatments onExpand
  • 141
  • 4
Models of Cancer Survivorship Care: Overview and Summary of Current Evidence.
INTRODUCTION This article, derived from a Technical Brief prepared for the Agency for Healthcare Research and Quality, presents an overview on current models of care for survivors of adult-onsetExpand
  • 85
  • 3
Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events.
Abundant research has now demonstrated that patient and clinician reports of symptoms—and particularly symptomatic toxicities (ie, adverse events) during cancer treatment—provide discrepant yetExpand
  • 82
  • 3
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
A MESSAGE FROM ASCO'S PRESIDENT Since its founding in 1964, the American Society of Clinical Oncology (ASCO) has been committed to improving cancer outcomes through research and the delivery ofExpand
  • 426
  • 2
  • PDF
Patient-reported outcomes in the evaluation of toxicity of anticancer treatments
Symptomatic toxicities associated with anticancer treatments, such as nausea and vomiting, are frequently underreported by clinicians, even when data are prospectively collected within clinicalExpand
  • 90
  • 2
Safety review of kava (Piper methysticum) by the Natural Standard Research Collaboration
This systematic review discusses the proposed uses, dosing parameters, adverse effects, toxicology, interactions and mechanism of action of kava. The widespread concern regarding the potentialExpand
  • 46
  • 2